Judy Phillips

1 POSTS 0 COMMENTS
Judy Phillips, Recruitment Director at chasepeople.com or call CHASE on 0131 553 6644 to find out more.

Latest articles

Antibiotic Research UK launches small research grants programme

Antibiotic Research UK launches small research grants programme

Antibiotic Research UK (ANTRUK), the world’s first charity tackling bacterial antibiotic resistance, has just launched its largest grants programme to date, the 2021 Small...
First AI-designed Immuno-oncology drug to enter clinical trials

First AI-designed Immuno-Oncology drug to enter clinical trials

Discovered within 8 months of project initiation, the first AI-designed molecule for Immuno-Oncology is to enter human clinical trials. The A2a receptor antagonist, which is in development...
ViiV Healthcare's long-acting injectable HIV treatment authorised in EU

The first self-administered B-cell therapy for patients with relapsing forms of MS

Novartis receives European and UK licence for Kesimpta®▼(ofatumumab) Ofatumumab is a self-administered targeted B-cell depleting treatment option for adult patients living with relapsing forms of...

Popular articles

Image of a person descending a ladder over coronavirus to show New Normal, New Thinking: Life Post COVID-19

New Normal, New Thinking: Life Post COVID-19

New thinking will be required to adapt to the new normal life post COVID-19. I hate to start this article on a negative note, but...
Image of a scientist at their lab to show Study shows existing anti-parasitic drug kills coronavirus within 48 hours

Study shows anti-parasitic drug ivermectin kills coronavirus within 48 hours

A collaborative study led by the Monash Biomedicine Discovery Institute (BDI) with the Peter Doherty Institute of Infection and Immunity (Doherty Institute), a joint...
ViiV Healthcare's long-acting injectable HIV treatment authorised in EU

The first self-administered B-cell therapy for patients with relapsing forms of MS

Novartis receives European and UK licence for Kesimpta®▼(ofatumumab) Ofatumumab is a self-administered targeted B-cell depleting treatment option for adult patients living with relapsing forms of...
New COVID-19 test reduces testing time from 30 minutes to five

New COVID-19 test reduces testing time from 30 minutes to five

University of Birmingham researchers have invented a COVID-19 test that reduces testing time from 30 minutes to under five, whilst still delivering accurate results. The...
First AI-designed Immuno-oncology drug to enter clinical trials

First AI-designed Immuno-Oncology drug to enter clinical trials

Discovered within 8 months of project initiation, the first AI-designed molecule for Immuno-Oncology is to enter human clinical trials. The A2a receptor antagonist, which is in development...

Subscribe

Sign up to receive your free UK subscription to Pf Magazine and our digital newsletters, for all the essential headlines, Jobs of the Week, and thought-provoking features.

Claim my free subscription